À retenir
Sarcopenia was diagnosed in 13 of 83 outpatients with type 2 diabetes (16.2%) versus 2 of 83 matched controls (2.4%; p = 0.01168). This is a single-clinic, cross-sectional comparison, so it shows an association and cannot show that diabetes causes sarcopenia.
Study design
Article de recherche
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
People with diabetes are at risk of poor mobility and strength, and sarcopenia (loss of muscle mass with reduced strength or performance) worsens outcomes in chronic disease. The authors measured how common sarcopenia is in type 2 diabetes and how it relates to disease features, complications and bone mineral density.
Population et méthode
Cross-sectional study of outpatients with type 2 diabetes (T2DM) diagnosed at least 1 year earlier at a university hospital endocrinology clinic in Brazil, from March to August 2016, compared with healthy controls matched for sex, age and race. Exclusions included chronic diseases, body-composition-altering drugs, BMI > 35 or < 18 kg/m^2, and supplements. Participants completed questionnaires and had dual energy absorptiometry (DXA), handgrip dynamometry and abdominal circumference measurement; diabetes data came from medical records. Sarcopenia followed the Foundation for the National Institutes of Health criteria.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1The final sample was 83 patients with diabetes and 83 controls. Patients had higher BMI, higher waist circumference, more past fractures, and lower calcium and healthy diet intake (p < 0.005).
- 2Abnormal bone mineral density was more frequent in patients, with osteopenia in 45 (53%) and osteoporosis in 14 (19%), plus more comorbidities (p < 0.005).
- 3Muscle weakness was present in 25 patients with diabetes (18 women) and 5 controls (4 men) (p = 0.00036), while pre-sarcopenia did not differ between groups.
- 4Sarcopenia was diagnosed in 13 patients (16.2%) versus 2 controls (2.4%) (p = 0.01168). It was associated with altered bone density (p < 0.005) but not with diabetes duration or control; BMI and osteoporosis raised the likelihood of sarcopenia, while hypertension and a healthy diet lowered it.
Limites et incertitude
- 1A single clinic in one region with 83 patients and 83 controls means few sarcopenia cases (13 and 2), so the estimates are imprecise and may not generalize.
- 2Cross-sectional data cannot show whether diabetes led to sarcopenia or the reverse, and the abstract reports no odds ratios or confidence intervals.
- 3Patients with other chronic diseases, BMI outside 18-35 and many drug users were excluded, so the sample is a selected, healthier group of people with T2DM.
- 4The abstract mentions worse glycemic control with altered bone density but also no association between sarcopenia and diabetes control, which makes the take-home message less clear. This reading is based on the abstract only.
Mise en perspective
The study suggests that people with type 2 diabetes may be more likely to have low muscle mass and strength, and that checking for it may be worthwhile. It does not tell you your own risk. Questions about muscle loss, bone health or diabetes care should go to your clinician.
Vos données
Handgrip and body weight are not common wearable data, but repeating a simple strength measure, such as logged lifts or grip strength, and daily steps from the same device can show whether you are keeping strength over time. Smart-scale muscle estimates are not equivalent to DXA, so rely on trends.
Comprendre ce type de preuve
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background
Diabetics are at increased risk for impaired mobility and strength, frequently related to the disease control. Sarcopenia is the reduction of muscle mass associated with the decrease in muscle strength and/or performance, resulting in worse morbidity in chronic diseases.
Methods
The objectives of this paper was to assess the prevalence of sarcopenia in patients with type 2 diabetes mellitus (T2DM) and determine its association with diabetes characteristics, progression, and complications, as well as changes in bone mineral density. The sample consisted of patients with T2DM followed at the outpatient clinics of the Serviço de Endocrinologia e Metabologia do Hospital de Clínicas da Universidade Federal do Paraná, from March to August 2016. Participants were men and women above 18 years with T2DM diagnosed at least 1 year earlier. Individuals with chronic diseases, users of any drug that modifies body composition, patients with body mass index (BMI) > 35 or < 18 kg/m^(2), and users of illicit drugs or hormonal or nutritional supplementation were excluded. The selected patients answered questionnaires about demographics, eating habits, and disease characteristics, and performed a bone densitometry exam in a dual energy absorptiometry (total body; spine and femur (total and neck)), a handgrip test by manual dynamometer, and an evaluation of the abdominal circumference (AC). The medical records were reviewed seeking diabetes data and laboratory test results. Patients were matched for sex, age, and race with healthy controls [Control Group (CG)]. The diagnosis of sarcopenia was conducted according to the criteria of the Foundation for National Institute of Health.
Results
The final sample consisted of 83 patients in the DG and 83 in the CG. The DG had higher BMI, WC, past history of fractures and lower calcium and healthy diet intake (p < 0.005), compared to the CG. The DG presented a higher frequency of abnormal BMD (osteopenia in 45 (53%), and osteoporosis in 14 (19%)) and comorbidities than the CG (p < 0.005). Pre-sarcopenia was not different between groups, but muscle weakness was present in 25 diabetics (18 women) and only in 5 controls (4 men) (p = 0.00036). Sarcopenia was diagnosed in 13 (16.2%) patients in the DG and 2 (2.4%) in the CG (p = 0.01168). Pre-sarcopenia and sarcopenia were associated with altered BMD (p < 0.005), with no association with diabetes duration or control. Body mass index and osteoporosis increased the likelihood to have sarcopenia, but hypertension and healthy diet decreased it.
Conclusion
The DG had altered BMD associated with worse glycemic control, and a higher prevalence of sarcopenia, suggesting the need to look for their presence in diabetics.
Sources et attribution
Sarcopenia: a chronic complication of type 2 diabetes mellitus.
Trierweiler H, Kisielewicz G, Hoffmann Jonasson T, Rasmussen Petterle R, Aguiar Moreira C, Zeghbi Cochenski Borba V.
Diabetology & metabolic syndrome · 2018-04-03
DOI: 10.1186/s13098-018-0326-5 ↗PubMed · 29632617 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

